Answers are grounded in this paper and cite their sources.
Hypoxia-inducible factors (HIFs) are central regulators of cellular adaptation to low oxygen, with a well-documented transition from HIF-1α to HIF-2α signaling during prolonged hypoxia. Here, we investigate the role of a natural antisense transcript of HIF1A, HIF1A-AS2, in modulating this transition in human endothelial cells (ECs). Genome-wide expression profiling revealed a strong hypoxia-induced upregulation of HIF1A-AS2 that coincided with a marked reduction in HIF1A mRNA levels, whereas EPAS1 remained stable. Interestingly, this negative correlation was consistent across multiple EC types and supported by silencing experiments which demonstrated that both HIF-1α and HIF-2α contribute to HIF1A-AS2 induction. Knockdown of HIF1A-AS2 partially restored HIF1A expression and increased HIF-1α protein and functional activity, as evidenced by elevated VEGFA and GLUT1 expression. Genomic analysis identified HIF-1 and HIF-2 binding motifs upstream of HIF1A-AS2, supporting the dual regulation. Furthermore, cancer tissue analysis revealed frequent downregulation of HIF1A-AS2, correlating with elevated HIF1A and EPAS1 levels. These findings suggest that HIF1A-AS2 acts as a hypoxia-responsive regulator that limits HIF-1α signaling and facilitates the HIF isoform switch, and suggests implications for endothelial adaptation, angiogenic signaling, and vascular remodeling under chronic hypoxia.
No takes yet. Share an insight, caveat, or question.
Barton et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: